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ABSTRACT 
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Supervisors: Dr. Barbara Jones, Lisa Kirsch, MPAFF 
 
Within the last forty years, the childhood cancer five-year survival rate has increased by 
more than 45%. The field of pediatric oncology has seen a tremendous growth in outcome and 
much of this success can be attributed to the diverse collaborative model that it is built upon. A 
multi-institutional research consortium which encompasses the majority of pediatric cancer 
treatment centers has led to an extraordinarily high participation rate in clinical trials and 
consequent surge in clinical and scientific knowledge. Child cancer patients are treated by 
collaborative oncology teams consisting of doctors from many geographical locations and in a 
variety of specialties. Furthermore, unilateral team-based care with a multi-disciplinary approach 
to treatment and the inclusion of fields such as physical therapy, nutrition, social work, and 
psychology has greatly improved outcomes. 
This thesis aims to further understand and characterize the field of pediatric oncology as a 
model of innovation and paradigm for success through collaboration rather than competition. 
The purpose of this research is also to understand areas for further growth within pediatric 
oncology and suggest methods to continue the current trajectory of innovation. This thesis will 
analyze how this collaborative model can be translated to other fields of medicine, including 
adult oncology, to spur similar growth. Finally, the ethical implications of treating children with 
cancer will be considered.   
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1  Introduction 
 
 Cancer has affected the lives of almost everyone, everywhere. The effects it has on 
the patient, their family, and their everyday lives are tremendous. Pediatric oncology, 
especially, places an undue burden on families and young children. This paper will begin 
by providing an overview of the current state and statistics of childhood cancer in the 
United States. Included in this background will be information on the pediatric oncology 
consortium and the nature of clinical trials. Following the background will be an 
overview of the unique aspects of pediatric oncology and a characterization of the 
different types of collaboration that define this field. Next, this thesis will analyze deficits 
in this model, identify areas for future growth, and propose solutions to spark innovation 
and address gaps in treatment. This thesis will then examine how this model of 
collaboration can be translated to other fields of medicine, such as adult oncology and 
other rare disease, to improve outcomes and spur growth. The key ethical considerations 
that must be taken into account in this field will be evaluated in order to ensure that the 
advances in treatment are ethically sound and put the patient’s best interests first. Finally, 
this thesis will evaluate the limitations of this model and its potential for transforming 
patient outcomes given the current state of healthcare. 
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2 Background 
  
Cancer is defined as the “group of diseases characterized by the growth and spread of 
abnormal cells”.1 It is the second leading cause of death in adults in the United States2 and 
although more rare in children, is still the second leading cause of death beyond infancy
3
. Even 
though only 1% of all cases of diagnosed cancer are in children
4
, it is estimated that in 2016, 
10,380 children under the age of 15 will be diagnosed with cancer.
5
 The amount of progress 
made in the field, both through scientific discoveries and treatment outcomes, has been nothing 
short of astounding.  In the mid-1970s, the 5-year survival rate after diagnosis was 58%
6
 in 
children but has dramatically risen to greater than 80% today.
7
 In contrast, adult 5-year survival 
is only at about 68%.
8
 The survival rate for adolescents between 15 and 19 is similar to that of 
younger children.
9
 There are no fixed criteria to label a disease as rare, but it is generally 
understood to be a malignant disorder which has an incidence of six or less per 100,000. By this 
definition, almost all childhood cancers would be classified as rare.
10
  
 The causes of most childhood cancers are unknown and are therefore highly difficult to 
prevent. The most common types of childhood cancers are leukemia (acute lymphoid leukemia 
                                                          
1
 Cancer Facts and Figures. American Cancer Society, 2015. 
www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf 
2
 Statistics for Different Kinds of Cancers. Centers for Disease Control and Prevention, 20 August 2015. 
www.cdc.gov/cancer/dcpc/data/types.htm 
3
 The primary cause of death in children is accidents. “Child Health.” CDC. 22 February 2016.   
www.cdc.gov/nchs/fastats/child-health.htm 
4
 Cancer in Children. American Cancer Society, 27 January 2016.  
www.cancer.org/cancer/cancerinchildren/detailedguide/cancer-in-children-key-statistics 
5
 Siegel, Rebecca L., Kimberly D. Miller, and Ahmedin Jemal. "Cancer statistics, 2016." CA: a cancer journal for 
clinicians 66.1 (2016): 7-30.) 
6
 Siegel, 29 
7
 Cancer in Children. 
8
 Cancer. NIH, 29 March 2013. https://report.nih.gov/nihfactsheets/viewfactsheet.aspx?csid=75 
9
 Cancer in Children and Adolescents. NIH: National Cancer Insitute, 12 May 2014. 
www.cancer.gov/types/childhood-cancers/child-adolescent-cancers-fact-sheet 
10
 Gatta, Gemma, et al. "Rare cancers are not so rare: the rare cancer burden in Europe." European journal of 
cancer 47.17 (2011): 2493-2511. 
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accounts for 75% of all childhood leukemias, brain/ONS cancer, lymphoma, sarcoma, 
neuroblastoma, Wilms tumor, and retinoblastoma. Leukemia, lymphoma, and brain/ONS cancers 
affect children the greatest and account for 64% of all cancers in children under the age of 15. 
The most frequently diagnosed cancer also varies by the age of the patient. While brain/ONS 
cancers are diagnosed in children of all ages, eye and kidney cancers are more common in 
younger children and lymphomas are more common in older children.
11
  
 The success of pediatric oncology is largely driven by the large allocation of resources to 
treating and curing it. There are an estimated 1,365 pediatric oncology specialists currently 
practicing in the United States.
12
 Not only have children’s cancer centers been developed13 but 
most of these centers are a part of the consortium known as the Children’s Oncology Group 
(COG), a phenomenon which is non-existent in adult oncology. The COG has an international 
presence and provides unique access to clinical trials and standardized protocols. Over 90% of 
children diagnosed with cancer are treated at a COG-affiliated center.
14
 A large part of the 
success in treating children comes from the prevalence of participation in research trials – 60% 
of children are enrolled in a clinical trial
15
 in which the control arm represents the best available 
therapy
16
 while less than 3% of adults participate in a trial.
17
 Also unique to the pediatric 
                                                          
11
 “An Analysis of the National Cancer Institute’s Investment in Pediatric Cancer Research.” National Cancer 
Institute, September 2013, https://www.cancer.gov/types/childhood-cancers/research/pediatric-analysis.pdf 
12
 “A Career in Pediatric Hematology-Oncology?” AAP. 7 March 2016. www.aap.org/en-us/about-the-
aap/Committees-Councils-Sections/section-hematology-oncology/Documents/career_brochure.pdf 
13
 Siegel  
14
 “About Us.” Children’s Oncology Group.  7 March 2016. www.childrensoncologygroup.org/index.php/aboutus 
15
 “Pediatric Clinical Trials.” Children’s Healthcare of Atlanta. 2016. http://www.choa.org/childrens-hospital-
services/cancer-and-blood-disorders/research/clinical-trials 
16
 Smith, Malcolm A., et al. "Declining childhood and adolescent cancer mortality." Cancer 120.16 (2014): 2497-
2506. 
17
 Unger, Joseph M., et al. "Comparison of survival outcomes among cancer patients treated in and out of clinical 
trials." Journal of the National Cancer Institute 106.3 (2014): dju002. 
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oncology treatment experience is treating more than just the cancer, the treatment teams for most 
children can also include nutritionists, psychologists, social workers, and other professionals.
18
   
 The development of a cancer treatment, particularly drug creation and treatment, is a 
lengthy process which requires intensive testing in humans.
19
  Before anti-cancer drugs are 
released on to the market, they must first be thoroughly tested which usually occurs through the 
occurrence of Phase I, II, and III clinical trials.
20
 The drug undergoes extensive pre-clinical 
development before Phase I testing has even begun. In any clinical trial, the number of 
participants must be considered. Too small of a trial may result in unreliable results, while a trial 
that is too large can waste resources and expose more patients than necessary to a potentially 
harmful treatment.
21
 
 About 60% of all biomedical research in the United States is funded by the private 
biopharmaceutical sector. The NIH supports 25% of research as the second largest funder. This 
situation is completely reversed in pediatric oncology. Almost all funding comes from the 
National Cancer Institute (NCI) within the National Institutes of Health (NIH), followed by 
private foundations and philanthropies, and the pharmaceutical industry contributes a negligible 
amount.
22
  
The purpose of the Phase I trial is to determine the Maximum Tolerated Dose (MTD) of 
the drug and the trial is performed in advanced cancer patients who may not be able to receive 
another treatment.
23
 In order to find the MTD, the treatment dose is escalated until the Dose 
                                                          
18
 Cancer in Children. 
19
 Ananthakrishnan, Revathi, and Sandeep Menon. "Design of oncology clinical trials: a review." Critical reviews in 
oncology/hematology 88.1 (2013): 144-153. 
20
 Griffiths, Gareth. "Clinical trials in oncology." Medicine 44.1 (2016): 56-58. 
21
 Smith, Catrin Tudur, Paula R. Williamson, and Michael W. Beresford. "Methodology of clinical trials for rare 
diseases." Best practice & research Clinical rheumatology 28.2 (2014): 247-262. 
22
 Adamson, Peter C., et al. "Drug discovery in paediatric oncology: roadblocks to progress." Nature Reviews Clinical 
Oncology 11.12 (2014): 732-739. 
23
 Smith, 2014 
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Limiting Toxicity (DLT) is reached. The pre-clinical phase will already have demonstrated that 
the drug is not lethal to humans and shows promise of benefit. Phase I trials often consist of 
patients with advanced cases who may not be able to receive another treatment as a part of their 
standard care. There are usually six to eight dosing levels with approximately three patients 
entered at a given time for a certain level.
24
 These trials usually only require a small number of 
patients, often in the dozens.
25
 In traditional Phase I studies, there is a very low chance of 
personal medical benefit and response rates have been estimated to be around only 5%.
26
  
Phase II trials require about a hundred patients or less with a specific type of cancer
27
 and 
these trials aim to test the safety and efficacy of a fixed dose of the drug, essentially acting as a 
screening stage.
28
  The goal of Phase II trials is to examine a drug for safety and dosing 
considerations in a dose-escalation model in order to further understand efficacy during Phase 
III. Most Phase II trials have historically designed as single-arm studies with no control group 
but recently there have been an increased number of randomized designs as the number of novel 
agents have grown. In randomized trials, trial participants are assigned to either the standard or 
novel treatment. The information gleaned on safety, activity, and feasibility is used to determine 
whether the trial should progress to the third phase.
29
 
Phase III trials, more commonly known as the randomized control trials, are double-blind 
and undergo rigorous statistical analysis to confirm that the benefit to ratio is high enough for 
drug approval.
30
 Essentially a Phase III trial aims to understand the clinical outcomes of novel 
                                                          
24
 Griffiths, 2016 
25
 Unger, 2014 
26
  Kodish, Eric. "Pediatric ethics and early-phase childhood cancer research: Conflicted goals and the prospect of 
benefit." Accountability in Research: Policies and Quality Assurance 10.1 (2003): 17-25.  
27
 Smith, 2014 
28
 Unger, 2014 
29
 Griffiths, 2016 
30
 Smith, 2014 
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agent in comparison to the control arm.
31
 During these phases, statistical analysis is used to test 
the null hypothesis, that there is no treatment effect, against the alternative hypothesis, that there 
is a treatment effect based on a significant sample size.
32
 Trials in this stage require at least 100 
participants, with numbers ranging from 100 to the thousands.
33
 The challenge for Phase III trials 
in the realm of rare diseases is that the trial design requires a large and sometimes unfeasible 
number of participants. Additionally, it is much more difficult to establish a standard of care to 
test the new therapies against because there is such little evidence available for different areas of 
case management.
34
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
31
 Griffiths, 2016 
32
 Billingham, Lucinda, Kinga Malottki, and Neil Steven. "Research methods to change clinical practice for patients 
with rare cancers." The Lancet Oncology 17.2 (2016): e70-e80. 
33
 “Phases of Clinical Trials.” National Cancer Institute, 2012, http://www.cancer.gov/about-
cancer/treatment/clinical-trials/what-are-trials/phases 
34
 Billingham, 2016 
10 
 
3  The Unique Model of Pediatric Oncology  
Children diagnosed with cancer are often regarded by society and the medical profession 
as one of the most important classes of medical patients. The progress of research and treatment 
is arguably the most significant development in the fight against childhood cancer in the last five 
decades.
35
 Unique to the experience of treating childhood cancer is the legacy of collaboration 
among medical subspecialties, institutions, study groups, and perhaps most significantly, 
between parents, researchers, and clinicians.
36
 Due to the relatively low rate of cancer incidence 
and the ratio of pediatric oncologists to patients, a cooperative model is inevitable and necessary 
to create rigorous treatments that can include clinical research trials.
37
  
 While most rare diseases have had slow growth and low resource allocation, childhood 
cancer has avoided that and has had accelerating progress. The successes of pediatric oncology 
have not been linear and it has not been caused by the development of new drugs. Rather, the 
innovation has occurred through testing existing adult chemotherapeutic agents in children 
coupled with advances in surgery, radiation, and intensive care.
38
The high level of participation 
in clinical trials which operate across different treatment centers and the structure of the pediatric 
oncology drug development industry have led to the creation of physician teams which can cross 
state and international boundaries. The existence of the COG has made this experience much 
more effective and the success of the different facets of the pediatric oncology specialty working 
                                                          
35
 Hudson, Melissa M., Michael P. Link, and Joseph V. Simone. "Milestones in the curability of pediatric 
cancers." Journal of Clinical Oncology 32.23 (2014): 2391-2397.  
36
Hudson, Melissa M., William H. Meyer, and Ching-Hon Pui. "Progress born from a legacy of 
collaboration." Journal of Clinical Oncology (2015): JCO-2015.  
37
 O'Leary, Maura, et al. "Progress in childhood cancer: 50 years of research collaboration, a report from the 
Children's Oncology Group." Seminars in oncology. Vol. 35. No. 5. WB Saunders, 2008. 
38
 Rose, Klaus. "New drugs for rare diseases in children." Clinical Therapeutics 39.2 (2017): 246-252. 
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together harmoniously largely explains the quality of cancer care and innovation that is found 
today.
39
  
 The collaborative and cooperative research of pediatric oncology has been instrumental 
in improving the lives of children diagnosed with cancer and lowering mortality rates by a 
significant amount. The incorporation of professionals from a wide range of backgrounds and 
training in different methodologies led to a faster spreading of ideas and greater novel 
approaches. This type of collaborative work has also facilitated the practices of consolidating 
data from a wider range of sources and comparing those results in order to improve outcomes. 
The cooperative groups have determined which are the most successful agents to be considered 
in RCTs by comparing alternate protocols and thoroughly examining different new therapeutic 
agents.
40
  
3.1 The Children’s Oncology Group 
 The COG was formed in 2000 when the four existing pediatric oncology clinical trials 
groups merged together.
41
 The four merging institutions included the Children’s Cancer Group 
(CCG), Pediatric Oncology Group (POG), Thabdomyosarcoma Study Group (TSG), and the 
National Wilms’ Tumor Study Group (NWTSG).42CCG was formed first in the 1950’s to 
separate treatments of type A and type B cancers. POG was born when the pediatric-focused 
members of the South West Oncology Group decided to separate from the parent organization 
and it subsequently expanded internationally.
43
 TSG and NWTSG grew from coordinated 
                                                          
39
 Harrod, Virginia. “Practicing Pediatric Oncology.” Plan II Premedical Society, February 2016, University of Texas 
at Austin. Guest Lecture.  
40
 Unguru, Yoram. "The successful integration of research and care: how pediatric oncology became the 
subspecialty in which research defines the standard of care." Pediatric blood & cancer 56.7 (2011): 1019-1025.  
41
 O’Leary, 2008 
42
 Benowitz, Steve. "Children’s oncology group looks to increase efficiency, numbers in clinical trials." (2000): 1876-
1878. 
43
 Murphy, Sharon. “On the Merger of the Pediatric Cancer Trials Cooperative Groups, National Cancer Policy 
Forum.” National Academies, 2009. 
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research trials for two rare cancer subtypes. 
44
While competition can be an incentive for 
innovation in certain situations, the four groups were competing for resources and money in an 
underfunded area to the detriment of patient care.  
Despite concerns that a scientific monopoly would be anti-intellectual, the COG has 
managed to create a huge number of trials and foster innovation,
45
 and now has also expanded 
into an international organization primarily supported by the National Cancer Institute.
46
 Most of 
its member institutions are either pediatric research centers or teaching hospitals.
47
 One of 
COG’s largest successes has been enrolling over 90% of its participating patients into a clinical 
study.
48
 Clinical trials have become the standard for care because pediatricians are willing to 
participate in protocols written by other investigators. Because the model of these trials is such 
that the best treatment from one becomes the standard regimen for the next trial, discoveries 
from the trials are quickly integrated into practice.
49
 This can be attributed to both patient 
registries and a partnership between large academic institutions and smaller community 
centers.
50
  
3.2 The Nature of Research in Pediatric Oncology 
The striking enrollment of patients into clinical trials has led to pediatric oncology 
becoming a paradigm for research.
51
 The leading centers of study can be found in the large 
academic institutions but smaller community centers encourage their patients to enroll in a large, 
                                                          
44
 O’Leary, 2008 
45
 Benowitz, 2000 
46
 Hansmann, Georg. "Interdisciplinary networks for the treatment of childhood pulmonary vascular disease: what 
pulmonary hypertension doctors can learn from pediatric oncologists." Pulmonary circulation 3.4 (2013): 792-801. 
47
 “Pediatric Clinical Trials” 
48
 “About Us” 
49
 Link, Michael P. "Collaborating to conquer cancer: Lessons from our children." Journal of Clinical Oncology 31.7 
(2013): 825-832. 
50
 Smith, 2014 
51
 Pizzo, Philip A., and David G. Poplack. Principles and practice of pediatric oncology. Lippincott Williams & Wilkins, 
2015. 
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centrally-managed trial. With this setup, each center can have a more reasonable workload and 
focus their treatment on one particular subspecialty.
52
 With this strong infrastructure to support 
clinical trials, smaller institutions are able to participate in groundbreaking research and 
disseminate those discoveries in areas which otherwise may not have access to the newest 
treatments. Because the large institutions serve as reference laboratories, the latest technology 
and rare expertise has become available to all patients and treatment centers.
53
  
 Furthermore, due to the limits placed by the small number of pediatric oncology cases 
every year, sample size constraints mandate the utilization of multicenter and multidisciplinary 
clinical trials because no single institution has a large enough sample size to perform an accurate 
randomized control trial (RCT).
54
 The COG enrolls patients from multiple hospitals into the 
same trial in order to have statistically significant results; this method is called collaborative 
research and is the basis for COG’s function.55 Pediatric drug oncology has historically lagged 
behind adult drug development because of the unique issues posed by the nature of childhood 
cancer; the diseases are rare and special trial designs are necessary to adjust for age-related 
dosage regimens and formulation as well as sampling schedules.
56
 Having a majority of the trials 
occur through the COG allows for the increased flexibility required to accommodate the special 
needs of treating childhood cancer.  
 The cooperative approach has many benefits for patient care. Physicians, patients, and 
parents are reassured that the treatment is the best possible because the protocols are written by 
acknowledged experts. Collaboration also allowed for access to tumor tissue which was crucial 
                                                          
52
 Adamson, 2014 
53
 O’Leary, 2008 
54
 “Pediatric Clinical Trials” 
55
 “Children’s Oncology Group, Who We Are.” Children’s Oncology Group, 2016, 
https://childrensoncologygroup.org/index.php/childrens-oncology-group 
56
 Rioux, Nathalie, and Nigel J. Waters. "Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology 
Drug Development." Drug Metabolism and Disposition 44.7 (2016): 934-943. 
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in understanding the mechanisms underlying childhood cancer. Information from tumors is key 
in determining risk stratification and course of treatment.
57
  
As more knowledge is gleaned about cancers the diagnoses of subclassifications are 
becoming more complex and risk-adjusted therapy approaches are becoming more prevalent, 
sample size issues have grown causing there to be increased international collaboration as well. 
Because many of these RCTs are run through the COG, the consortium has been able to 
amalgamate patient data, scientific ideas, and other resources resulting in a faster than normal 
rate of innovation.
58
 The well-defined treatment protocols put forward by the COG have greatly 
improved the survival of children compared to those who are treated in a center which is not a 
consortium member.
59
 The standardization of care and the participation of almost all childhood 
cancer treatment centers have caused the COG to become a mechanism for collaboration and 
innovation almost unparalleled in the medical field.  
Furthermore, most pediatric oncologists are involved in clinical care and research 
because occurrences of childhood cancer are so rare and the results of studies done in adults 
usually cannot be generalized to children.
60
 In order to prevent huge time lags before a drug 
becomes available for children, a greater percentage of participants need to be recruited for trials 
pediatric oncologists have to be investigators as well.
61
 The integration of research and medical 
care makes each oncologist a valuable resource of information, especially when there is such a 
rare occurrence of each type of pediatric cancer.
62
 For example, even leukemia, which is the 
                                                          
57
 Link, 2013 
58
 Unger, 2014 
59
  Bleyer, W. A. "The US pediatric cancer clinical trials programmes: international implications and the way 
forward." European Journal of Cancer 33.9 (1997): 1439-1447. 
60
 de Vries, Martine C., et al. "Ethical issues at the interface of clinical care and research practice in pediatric 
oncology: a narrative review of parents' and physicians' experiences." BMC medical ethics 12.1 (2011): 18. 
61
 Hudson, 2014 
62
 Hudson, 2015 
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most common type of childhood cancer, only accounts for 30% of occurrences. The second most 
common are brain and nervous system cancers (26%) followed by soft tissue sarcomas (7%).
63
  
3.3 Multidisciplinary Treatment 
 Pediatric oncology pioneered the multidisciplinary approach of treatment.
64
 The long-
established pediatric oncology model dates back to the 1950s and consists of a multidisciplinary 
approach for diagnosis, treatment, and long-term follow-up.
65
 Investigators from different 
specialties joining together to expedite breakthroughs and build on early success has long been 
the norm.
66
 This methodology of treatment has been advanced even further through the 
guidelines established by the American Academy of Pediatrics for pediatric cancer centers, 
which stipulate that each center must have a functional multidisciplinary team dedicated to 
providing optimal care.
67
  
Each treatment team includes a variety of specialists. For example, the multidisciplinary 
team of the pediatric oncology department at Massachusetts General Hospital includes child 
psychiatrists, social workers, child life specialists, nutritionists, physical therapists, and 
rehabilitation medicine specialists.
68
 This interdisciplinary approach has been integral in 
treatment and supportive care and has led to significant improvements in survival and quality of 
life.
69
 One of the most integral members of the team is the mental health professional who 
interacts with the lead oncologist on at least a daily basis and the quality of psychosocial care of 
                                                          
63
 Siegel, 2016 
64
 “Cancer in Children and Adolescents” 
65
 Pritchard-Jones, Kathy, et al. "Sustaining innovation and improvement in the treatment of childhood cancer: 
lessons from high-income countries." The lancet oncology 14.3 (2013): e95-e103. 
66
 Rioux, 2016 
67
 Cantrell, Mary Ann, and Kathy Ruble. "Multidisciplinary care in pediatric oncology." Journal of Multidisciplinary 
healthcare 4.1 (2011): 171-181. 
68
 “Division of Pediatric Hematology and Oncology.” MassGeneral Hospital for Children, 2016,  
http://www.massgeneral.org/children/services/treatmentprograms.aspx?id=1610 
69
 Rioux, 2016 
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children affected with cancer is far superior to that of adults.
70
 While psychologists are a 
component of many teams, it is usually the social worker that serves as the coordinator for 
psychosocial care, especially in COG-funded institutions.  
3.4  Multi-physician Teams 
 Collaboration among pediatric oncologists is necessary for a variety of reasons and 
cooperation to this extent is not seen in adult oncology. The relatively low number of cases and 
high importance of these patients have led to a team-based approach to treatment. If each patient 
only had one oncologist there would not be enough cases for each physician and quality of care 
would decrease. Because children with cancer are one of the highest priority patients, hospitals, 
families, and the healthcare system are willing to allocate generous resources to their treatment, 
specifically in the form of multiple doctors consulting for one patient.
71
 Additionally, as 
diagnoses and treatments are becoming more complex specialists in different fields are needed. 
For example, a child with a liver tumor may require a radiation oncologist, oncological surgeon, 
and hepatologist in addition to their oncologist. Each physician must be involved at every step of 
the treatment plan in order to increase benefits and mitigate any risks.
72
 Experts of rare cancers 
oftentimes perform on-treatment review, allowing oncologists with limited experience access to 
knowledge they otherwise would not have.
73
 While this type of cooperation exists in adult 
oncology, it does not match the level and success of that seen in children’s cancer care.  
 Collaboration between physicians is also the result of the way in which the drug industry 
and research trials operate. Rather than improving the efficiency of a drug, pharmaceutical 
companies and drug developers create a new drug which has the same end result but with a 
                                                          
70
 Wiener, Lori, et al. "Pediatric psycho‐oncology care: standards, guidelines, and consensus reports." Psycho‐
Oncology 24.2 (2015): 204-211. 
71
 Ananthakrishnan, 2013 
72
 Cantrell, 2011 
73
 Murphy, 2009 
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higher percentage of success and different biological method.
74
 Additionally, oncology drugs 
have some of the highest rates of attrition because of unexpected toxicity or inefficiency.
75
 
Because of this, new oncology drugs are constantly being released and input from different 
oncologists is necessary because it is close to impossible for one physician to know every drug 
available and its effects on a child.
76
  
 Collaboration among pediatric oncologists has also been naturally heralded through 
systems of drug labelling. Modern drug labels require proof of efficacy, including dosage 
information for children, through clinical and regulatory trials. While labelling improved in the 
1960’s and 1970’s, the successes of pediatric oncology did not arise from better product 
labelling. Children with cancer are treated by highly specialized oncologists who rely on off-
label treatments based on nonregulatory clinical trials. As modern labels have increasingly 
replaced eminence-based decision making, the studies need collaboration by multiple physicians 
to implement the trial, learn from them, and properly disseminate the new information.
77
  
3.5  Major Success Stories: Acute Lymphoblastic Leukemia (ALL) & Ewing’s Sarcoma 
 Extraordinary progress has been made in acute lymphoblastic leukemia (ALL) in recent 
years through national and international collaborative research resulting in cure rates of 80% in 
most industrialized countries.
78
 The bone marrow overproduces immature lymphocytes, a type of 
white blood cells, in ALL and red blood cells, white blood cells, and platelets can be affected.
79
 
About 3,000 individuals under age 20 are found to have ALL each year in the US and current 
                                                          
74
 Ananthakrishnan, 2013 
75
 van Hasselt, JG Coen, and Piet H. van der Graaf. "Towards integrative systems pharmacology models in oncology 
drug development." Drug Discovery Today: Technologies 15 (2015): 1-8. 
76
 Smith, 2014 
77
 Rose, 2017 
78
 Pui, Ching-Hon, and Raul C. Ribeiro. "International collaboration on childhood leukemia." International journal of 
hematology 78.5 (2003): 383-389. 
79
 “Childhood Acute Lymphoblastic Leukemia.” National Cancer Institute, 5 February, 2016,  
https://seer.cancer.gov/statfacts/html/alyl.html 
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treatments involve a mix of chemotherapy, stem cell transplant, radiation, and targeted therapy.
80
 
Collaboration has been integral in developing optimal therapy and supportive care for the 
different types of ALL. A standard therapeutic approach for rare subtypes, such as myeloid 
leukemia in patients with Down syndrome, has been developed through the partnership of 
various cooperative research groups.
81
 These developments were largely supplemented by 
international collaborations, including an agreement to combine data from studies between the 
Associazone Italiana di Ematologia ed Oncologia Pediatrica, Berlin-Frankfurt-Munster Study 
Group, the Children’s Cancer Group, and St. Jude’s Children Research Hospital.82  
 Treatment of Ewing’s sarcoma (ES), a tumor of bone and soft tissue, has made 
remarkable progress due to multidisciplinary and international collaborations. The sarcoma 
usually arises in the bones of the arms, legs, pelvis or chest. Chemotherapy is usually performed 
first to shrink the size of the tumor followed by surgical removal.
83
 About 200 children are 
diagnosed with Ewig’s sarcoma every year in America and about 70% of children with it are 
cured.
84
 However, if the disease is diagnosed after it has spread the survival rate is only 30%.
85
 
Progress in surgical options and aggressive radiation therapies have both led to large 
improvements in outcomes. Collaboration between physicians, pathologists, and biologists at an 
international and national level has led to a virtual and centralized biobanking system with 
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pretreatment diagnostic ES samples. Cooperative trials in America and Europe have also led to 
advances in finding a cure and optimizing multimodal therapeutic strategies.  
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4 Areas for Further Growth 
 Despite the dramatic rise in survival rates there are still many areas in which pediatric 
oncology can improve to yield further growth. The field continues to face many challenges to 
achieving high survival rates for all types of cancer and this section will focus on what areas hold 
the most promise for growth and what opportunities there are for improvement. Advances in 
treatment, particularly in the rise of biomarkers and personalized genomics, present unique 
avenues that can be capitalized upon for better therapeutic agents. Despite historical growth, the 
current state of child cancer research and treatment will be discussed and the claims of a plateau 
in innovation addressed. Because drug development continues to be a challenge in treating 
pediatric cancer patients, the nature of the pharmaceutical industry within pediatric oncology will 
be explored and recommendations will be given for overcoming barriers within pharma. Policy 
responses to drug development will also be considered. Finally, specific recommendations to 
spur further innovation will be presented.   
4.1  The Use of Genomics in Cancer Treatment 
 Cancer genomes amass somatic mutations, including single nucleotide substitutions, 
insertions or deletions, copy number changes, and chromosomal rearrangements.
86
 As a result of 
massive parallel genomic micro- and nanoarrays, complete genome sequencing is becoming 
more available at a lower cost. Personal genome sequencing (PGS) can provide a better 
understanding of the molecular processes involved cancer metastasis and development as well as 
improve tumor diagnosis.
87
 Cancer mutations are diverse in type, number, and functional effects 
but the genetic markers which PGS tracks can create a mutation profile which indicates 
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susceptibility to disease and likely responses to certain drugs.
88
 PGS allows for more optimal 
treatments, including repurposing drugs for new purposes and diseases.
89
 Collaboration has been 
the driving force in The Cancer Genome Atlas (TCGA), an American endeavor to profile the 
genomic changes in major types and subtypes of cancer. TCGA has been a collaboration 
between the National Cancer Institute and National Human Genome Research Institute. It has 
operated as a national network of research and technology teams which has pooled their results 
and made their data available for free internationally. This coordinated effort has allowed for the 
characterization of 33 cancers from tissues of over 11,000 patients.
90
 The collaborative model 
has expanded to an international effort through the creation of the International Cancer Genome 
Consortium, a merging of the efforts between Canada and the United States.
91
  
 PCG is not completely reliable and there are still many concerns over the validity and 
clinical utility of these tests.
92
 One way to make this method more applicable and ease concerns 
is by creating a multidisciplinary research agenda composed of epidemiology, clinical biology, 
behavioral science, and public health. Clinical studies are necessary to test the effectiveness of 
PCG data and health services research to ensure the integration of this data into clinical practice 
is being done in a beneficial way. Epidemiologic studies are necessary for risk characterization 
and public health research can test if these endeavors are cost-effective and reduce health 
disparities.
93
 Clinical applications will also be improved if the knowledge of oncologists, 
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pathologists, biostatisticians, geneticists, policy-makers, and pharmacists is combined in a 
coordinated effort.
94
   
4.2 Pharmaceutical Considerations: Problems in Drug Development and Recommendations 
 Children with cancer face a major lack of access to new drugs.
95
 High income countries, 
such as the United States, have almost reached an optimization of current anticancer treatments 
and the growth in rate of survival has greatly slowed since the early 2000s.
96
 Scientific progress 
in treating pediatric oncology has also slowed down because the small market of pediatric 
oncology fails to provide enough incentive for pharmaceutical companies to vigilantly pursue 
treatments and cures.
97
 The majority of oncology drugs are first developed for adults and then 
used to treat children after enough years have passed to fully understand its effects. In the past 20 
years, only one drug has been developed for pediatric cancer indications.
98
 Currently, the 
industry begins to consider developing a drug for the pediatric cancer patients only after it has 
reached phase II trials in adults. If there is not sufficient preclinical data to inform this drug 
development then the process lags even further.
99
 
 Registering a new therapy for pediatric patients of rare diseases adds another level of 
complexity to the already difficult drug development process. Disease-specific strategies are 
needed to engage with parents, caregivers, and a variety of advocates are needed in order to 
identify and engage pediatric patients. Qualitative measures of treatment evaluation are also 
difficult to develop because a child may not be able to read a questionnaire, understand the 
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concepts being asked of them, or provide a reliable answer to those questions. Clinical outcome 
assessments are usually completed by a parent or a caregiver because they have been present as 
the disease and treatment have progressed over time.
100
 As a result, the FDA has recommended 
that observable measures should be evaluated when gathering informant-reported measures.
101
  
 While conventional drug development operates in a fairly linear pattern, the opposite is 
true for rare diseases. Different groups of people oversee each step of a conventional drug 
development. The leadership of research and development, such as a chief scientific officer of a 
pharmaceutical company, will interact with academia and discovery laboratories when they 
identify a drug of interest. Once a lead has been identified, the clinical development team of a 
pharmaceutical company will work with investigators and regulators to begin trials. After the 
drug has gone through regulatory approval, commercial and medical affairs work with leaders in 
the medical community and patients to deliver the treatment. While there is some overlap, each 
group is usually made of different individuals. In rare diseases, however, there is a large amount 
of overlap. Investigators are often members of the medical community, patient advocacy 
organizations have close ties with investigators, and there is greater collaboration between 
researchers, healthcare providers, and regulatory agencies. Therefore, research and development 
priorities need to be agreed upon early to ensure a smooth process, especially when there are a 
limited number of patients.
102
  
 Research consortia can also be used to improve relations with and serve as a bridge 
between pharmaceutical companies, patient advocacy groups, primary care doctors, and other 
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health professionals. It has been widely regarded that pharmaceutical companies are generally 
unwilling to perform trials of new drugs for rare cancers because of limited financial return. 
However, this trend has begun to reverse in recent years and the question now is how to further 
incentivize drug companies to pursue these avenues. The reversal has occurred for a number of 
reasons. One, niche indications sometimes cause faster drug registration with regulatory agencies 
because there are no other treatments with significant levels of efficacy. Second, if a rare tumor 
has a well understood driver mutation then the efficacy of a drug can be validated without an 
RCT because it causes greater tumor response and progression-free survival in patients. Finally, 
health agencies, patient advocacy groups, and other entities have provided support to create 
drugs for rare diseases.
103
   
 Molecularly targeted therapy holds great promise for treating childhood cancer, 
especially rarer subtypes. However utilization of these strategies faces unique problems in 
pediatric oncology. Implementation requires an extensive knowledge of the molecular targets 
and signaling pathways, but this underlying biology differs vastly between adults and children 
making it difficult to translate high-priority targets in adults to children. Additionally, many 
pediatric cancers are more genetically complex than adult malignancies, and this heterogeneity 
makes the cancer more difficult to treat with single agents.
104
 
 As the saying goes, children are not small adults. Drug dosages are developed in a way 
that they can be applied to the entire adult population, which poses a serious barrier to their use 
in children. Physical and developmental changes during childhood affect drug absorption, drug 
distribution in tissues, and metabolic enzyme expression. The National Cancer Institute (NCI) 
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began the Pediatric Preclinical Testing Program (PPTP) in 2004 as a multi-institutional program 
for testing new agents in development for the applicability to childhood solid tumors and 
leukemia using in vivo xenograft studies.
105
 This program performs testing on pediatric tumors to 
decide which agents should be prioritized in trials.
106
  
 As the knowledge of the molecular basis of cancer increases, types of cancers are 
growingly clustered into sub-species based on their genomic biomarkers. This poses an 
important problem for pediatric oncology as many childhood cancers are already rare and a 
biomarker does not always have a corresponding drug in existence. The extremely high costs for 
research and development of drugs for specific biomarkers and rare diseases are very prohibitive 
which makes it highly unlikely that private corporations will pursue research in these subtypes. 
Therefore, more public-private partnerships will be essential in ensuring that R&D for rare 
subtype treatment is actually pursued.
107
  
Biopharmaceutical companies and public research groups will also have to look towards 
an international collaboration approach to be able to recruit enough participants for their trials. 
Global coordination will be most necessary in phase 2 trials, which mostly use randomized 
methods, and phase 3 trials in patients with selected biomarkers.
108
 In order for international 
trials to become more common, definitions of response need to be synchronized between 
partnering entities, particularly between North America and Europe.
109
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4.3  Policies to Incentivize Drug Development 
Within the last twenty years, many important policies and regulatory changes have 
incentivized pediatric drug development, including The Best Pharmaceutical for Children Act of 
1997, the Pediatric Research Equity Act of 1997, and the Creating Hope Act of 2010.
110
 The goal 
of the first two acts was to incentivize the pharmaceutical industry to increase their knowledge of 
the impact of their drugs on pediatric patients. These two acts have significantly increased the 
number of drugs with pediatric labeling and have led to the novel use of more than 400 drugs in 
children.
111
 The acts also increased communication between the biopharmaceutical and pediatric 
oncology clinical research industries.
112
 Pediatric development plans are required to be 
considered at the end of Phase 2 trials, which hypothetically should lead to earlier creation of 
pediatric evaluation requests in the drug-development timeline.
113
 However, many companies 
received waivers from having to test drug effectiveness in children because cancer drugs are 
labeled based on pathological traits which allowed relevant but pathologically distant pediatric 
cancers to be avoided.
114
  
While many of the unique aspects of pediatric oncology can be applied to the adult field, 
it is also important to increase collaboration between researchers in adult and pediatric oncology. 
Due to the nature of pediatric cancer drug development, the adult oncology drug field must be 
able to efficiently and effectively share their knowledge and data with pediatric researchers. It is, 
however, important to note that while it may take time for breakthroughs in adult cancer 
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treatments to reach pediatrics, improved treatment regimens diffuse quickly for childhood 
cancers due to the high participation of patients in clinical trials.
115
  
 The Creating Hope Act of 2010 is a priority review voucher
116
 with the FDA
117
 meant to 
incentivize the development of new drugs exclusively for rare pediatric diseases. Successful drug 
development for rare diseases such as pediatric oncology requires collaboration between the 
government and industry. The government can enable early studies to reduce the risk of 
candidate drugs, but the pharmaceutical industry is needed for later clinical development and to 
actually produce the products.
118
 The transformation of adult drugs into pediatric drugs by 
pharmaceutical companies, however, can come at a cost. The companies developing adult drugs 
must meet regulatory requirements for those products which take the focus away from groups 
solely focusing on pediatric oncology. This causes the highly integrated and collaborative 
pediatric oncology community to become fragmented and jeopardizes the unified clinical 
activities which are needed for the small number of child cancer patients.
119
   
4.4 Recommendations for Further Innovation and Collaboration 
 The recent plateau in mortality rates and remaining cancers with very poor treatment 
outcomes clearly demonstrate that there is a strong need for the development of novel therapies 
and modifying the use of currently available chemotherapeutics is not sufficient.
120
The cell 
signaling pathways in cancer cells have undergone multiple mutations and treating only one 
pathway oftentimes leads to relapse or resistance. Therefore, combination therapies which target 
multiple pathways are key to improving response and studies have shown that treatment with two 
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drugs simultaneously is much more effective than sequential treatment.
121
 This type of therapy, 
however, commonly requires drugs with intellectual property rights held by different companies 
and collaboration among companies, organizations, and institutions is oftentimes difficult.
122
  
 In a structure with this level of collaboration it is important to ensure that interests of 
different stakeholders are considered and respected through the course of treatment development. 
These players, including pharmaceutical companies, academic institutions, hospitals, and 
government regulatory agencies, have different institutional cultures which can hinder 
cooperative efforts. Misaligned or different goals can lead to issues regarding intellectual 
property, publication policy, conflict of interest, antitrust, or rewards. Perhaps even more 
harmful is an “insular” system in which the movement of ideas and information is restricted 
which may also have severe consequences on the timeline of drug development.
123
  
 One way to incentivize development is by providing increased funding for coordinated 
efforts that are composed of teams from different organizations and disciplines.
124
 Following the 
model created by Stand Up To Cancer (SU2C) and creating these types of agencies specifically 
for pediatric oncology which replicate this methodology can entice innovation and collaboration. 
SU2C provides the “Dream Team” grant to multi-institutional groups of scientists who are 
working together rather than competing and the “Innovative Research” grants to cancer research 
projects which are high-risk but also high-impact. The actual funds are managed by the 
American Association for Cancer Research (AACR) while grant management and allocation is 
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controlled by a committee of clinical investigators, physicians, and other experts in the field.
125
 
Because the grants are primarily for translational research, delineating funds specifically for 
collaborative efforts or high-risk/high-reward endeavors in childhood cancer can incentivize the 
development of new drugs for children during this time of severe shortage.  
Establishing a multisite clinical trial can take years and new scientific developments may 
already have occurred in that time. During the creation of these trials, each institution must 
receive Institutional Review Board (IRB) approval independently which poses a major time 
limitation. Ensuring that each participant is presenting a strong trial concept initially to the IRB 
and frequent communication between all parties may accelerate the approval process.
126
 Another 
method of expediting the process could be by establishing a system in which all institutions 
receive approval for pediatric cancer trials at once. This would be feasible in the field of 
pediatric oncology because previous trials will have involved the same players and the trial will 
be led by one large institution serving as the hub for coordination. Earlier involvement of the 
FDA in pre-IND (Investigational New Drug) trials, especially when combination therapies are 
being tested, can prevent later regulatory issues. 
Precompetitive collaboration, or collaboration between companies, has been identified as 
a promising method to make drug development more efficient and create value in the biomedical 
industry. Collaborative approaches in industry are becoming a necessity as development 
complexity and costs keep increasing, and it is very rare for one company to have the resources 
to address the mechanisms by which cancer cells gain resistance to treatment.
127
 Precompetition 
and noncompetition is especially useful in compounds which act on the same molecular target or 
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complementarily affect the same pathway.
128
 In theory, pre-competitive collaboration allows 
competitors to pool resources and intellectual property to improve the emergence of new 
technologies and address industry-wide problems. Historically, governmental agencies such as 
the NIH, FDA, and NSF have assisted in the creation of pre-competitive consortia and 
collaborations for their respective fields.
129
 A major motivator for precompetitive collaboration 
in the pharmaceutical industry is the fact that medical innovation and drug discovery requires an 
understanding of increasingly complex biology.
130
  
The TransCelerateBioPharma initiative has been an example of a successful 
precompetitive partnership, consisting of fifteen pharmaceutical companies, including 
AstraZeneca, Merck, Amgen, and Pfizer. TransCelerate was launched as a nonprofit in 2012 and 
has launched a subsidiary to increase efficiency in preclinical research as well as many initiatives 
which streamline the trial process and make it uniform for participating organizations.
131
 
AstraZeneca and Merck also successfully collaborated in the development of a combination 
therapy for cancer, with each player contributing a therapeutic agent. AstraZeneca had developed 
an agent to block the MEK cellular pathway while Merck had developed one for the Akt 
pathway; both are important signaling pathways in carcinogenesis and each can act as a backup 
for the other. Especially when there is only a 5% success rate for anticancer agents in the drug 
development pipeline, and lower for pediatric cancers, precompetitive collaboration should be 
pursued to address the growing complexity of cancer biology.
132
 Besides making drug 
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development faster and less risky, precompetitive collaboration fosters creative thinking, brings 
scientists of various backgrounds together, and sparks innovation.
133
 
Pediatric oncology institutions in the United States may benefit from using aspects of the 
franchise-based database model used by the International Cancer Genome Consortium. Because 
the members are so fragmented, information needs to be integrated and made available to the 
public. Each member copies its tumor analysis results into a local franchise database, all of 
which have the same schema to describe tissue samples, clinical information, and genome 
categorization data. The primary data files are sent to the US National Center for Biotechnology 
Information (NCBI) or the European Bioinformatics Institute (EBI) while interpreted data sets 
are stored in franchise databases. A data coordination center has been created to manage the data 
flow.
134
 The application of this model and the creation of a specific data coordination center can 
be applied to the Children’s Oncology Group so that there is greater information sharing between 
pediatric trials as well as a larger flow of data from adult trials to pediatrics.  
4.5 Sustaining Growth in Pediatric Oncology 
 Treatment of childhood cancer has been one of the success stories of medicine in the 20
th
 
century. Despite these successes, by the turn of the century slightly greater than 20% of 
childhood cancer patients still died because of their disease and those that survived faced 
significant long-term effects. Additionally, different cancer subtypes have faced unequal growth 
as hematologic malignancies have had a much larger rate of progress than in solid tumors. Acute 
lymphoblastic leukemia, acute myeloid leukemia, and non-Hodgkin lymphoma have contributed 
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the most to improved survival rates.
135
  In contrast, progress has been very limited in certain 
cancers, including high-grade gliomas and metastatic sarcomas. For example, there currently is 
no effective treatment for diffuse intrinsic potine glioma which has a 9-month median survival 
and expected death within 18 months.
136
  
 Patterns of mortality are significantly different between adolescents (15 – 19 years of 
age) and younger children (<15 years of age). Studies by Smith, et al. which examined mortality 
patterns between 2007 and 2010 revealed that brain tumors, neuroblastomas, and leukemias 
accounted for 71% of cancer-related mortality in the younger children, but only for 46% in the 
adolescents. One-third of mortality in adolescents could be accounted for by bone and soft tissue 
cancers and Non-Hodgin’s Lymphoma, but these cancers cause less than one-sixth of the deaths 
in younger children.
137
 Addressing these disparities and developing treatments based on these 
trends is integral to lowering mortality rates among all age groups and cancer subtypes.  
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It is important to note, however, that while there are differences in the causes of cancer-
related mortality between children and adolescents, adolescents have also seen impressive 
improvements in survival despite their much lower participation in clinical trials compared to 
younger children.
138
 Adolescents (ages 15-19) are often viewed as residing in a “no-man’s land” 
between childhood and adult cancers, and a major reason for their low participation in clinical 
protocols is low awareness that cancers occur within this age group. While most adolescents are 
treated at adult facilities, 60 – 75% of their cancers are actually typical of those in the pediatric 
age range. Their treatment should therefore be determined not by their age but by the type of 
tumor, whether it shows characteristics of “adult” or “pediatric” tumors.139 This method would 
not only improve their chances of survival but also increase participation in clinical trials and 
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increase the potential number of patients that can be integrated into pediatric trials. The 
additional recruitment of patients from the adolescent age group may in fact improve research 
methods and clinical protocols for both adolescents and younger children.  
 Rare pediatric tumors make up 10% of all childhood cancers and their diverse histologies 
and clinical characteristics have made them difficult to be thoroughly researched. The number of 
children with these cancers is so low that these diseases are not included in current registries or 
treatment protocols.
140
 Different entities define rare pediatric cancers in different ways, and there 
is no uniformly accepted definition within the realm of pediatric oncology.
141
 The European 
Cooperative Study Group for Pediatric Rare Tumors defines it as a cancer with an incidence rate 
of ≤ 2 per million per year, not considered in clinical trials, or both. Therefore, a cancer with a 
lack of registries and trials would be considered rare regardless of its incidence rate, such as 
pediatric melanoma.
142
 The COG, in contrast, utilizes a histological approach and defines rare 
cancers as “other malignant epithelial neoplasms and melanomas.” An international collaborative 
endeavor to reach a consensus on the definition can improve policy and research efforts towards 
this under-adressed group of cancers. 
 Improvements in 5-year survival rates have not been uniform amongst all childhood 
cancers. Children with high-risk neuroblastomas have a 5-year survival rate of less than 50%. 
Outcomes are also poor in patients with soft tissue sarcomas and malignant bone tumors that 
have spread beyond their primary site. Low prognosis in these fields demonstrates a need for 
new therapies and treatments.
143
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 Neuroblastoma (NB), for example, occurs in very young children with a median age of 
diagnosis at 17 months. Although neuroblastomas only account for 5% of all pediatric cancer 
diagnoses, they account for 10% of all childhood mortalities.
144
 While a number of different 
therapies are being developed to treat this disease, molecularly targeted agents are seen as the 
most promising strategy. Even though the agents have individual promise, the greatest potential 
lies in combination therapies. As a result, most phase II studies in NB use an experimental agent 
in combination with a chemotherapeutic backbone. To fully take advantage of these developing 
therapies different mechanisms will need to be developed to and different suggestions have been 
made to improve therapeutic outcomes.  
 Personalizing the approach towards targeted therapies poses one of the most significant 
challenges but could offer a high benefit in outcome improvement. Specific genetic mutations in 
NB are rare but identifying certain mutations in protein inhibitors could be used to predict 
response to therapies. The issue in this domain is integrating such testing into routine clinical 
management. Doing so will require greater communication and work between researchers 
identifying mutations and pediatric oncologists. Not all targeted therapies have readily available 
predictive biomarkers and as such there is currently no way to predict response to a certain agent 
and inform on therapy choice in cases of relapse.
145
 One method to overcome this problem would 
be to create profiles of specific tumors using DNA sequencing, gene expression arrays, and 
phospho-proteomics.
146
 Such a profile could be used to identify which molecular signaling 
pathways have been activated and therefore provide information on which specific molecular 
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agent would be the best choice in inhibiting those pathways. Especially in cancers with a high 
rate of relapse, such as NB which has a rate of close to 50%, molecularly targeted agents may 
offer the chance if not to cure the disease, then at least to manage it and transform it into a 
chronic instead of fatal disease.  
 In these types of Phase II studies, however, patient selection criteria will become 
especially important as the molecular targeted therapies may only affect those with a specific 
molecular phenotype while the overall group of participants may not see significant 
improvements. This may lead to a therapy being abandoned prematurely. Especially given the 
low number of children diagnosed with NB, in order to adequately select patients for phase II 
trials researchers and clinicians may have to establish international response criteria.
147
  
 Improving treatment success for rare pediatric cancers is most likely to improve through 
increasing the referral base for trials of these tumors. Trial recruitment is not the only issue as 
there is a serious lack of understanding of the biological characteristics of these tumors. 
Therefore, there needs to be greater access to tissue samples, registries, and patient data on a 
national and international level. While partnerships, for cancers such as melanoma, with adult 
groups have not proven successful due to infrastructure and funding limitations, collaboration 
should continue to better translate treatment options for children.
148
  
 Over the last decade many have claimed that conventional anti-cancer treatments have 
been optimized in high-income countries as the rate of decrease in mortality has been slowing 
since the early 2000s
149
 and that minimal improvements are possible moving forward.
150
 While 
survival rates for some cancers such as leukemias and lymphomas have continued to improve 
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over the last fifteen years, the declines in mortality have slowed by approximately 2% every 
year. Furthermore, 5-year survival rates for solid tumors other than neuroblastomas, especially 
sarcomas, have not changed in the last 15 – 20 years, and there have only been modest 
improvements in brain tumor survival. 
 The improvement in outcome for children with cancer has closely paralleled the 
organizational developments and transformations of the pediatric oncology field. The initial 
formation of the COG and the period of peak activity of cooperative multicenter clinical trials 
groups were times which saw the greatest growth in outcome. The decreases in mortality rates 
are also closely correlated with the times of intense focus on exploring multimodal therapeutic 
approaches, which eventually developed into the standards of care for the disease.
151
  
 
However, long-term effects of cancer therapies also need to be taken into account. Being 
cancer free does not equate to being free of cancer’s effects. Survivors often face significant 
medical and psychological complications later in their life, and therapies which lessen the 
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occurrences of these side effects should continue to be pursued, regardless of its curative traits. 
Drugs which achieve the same, if not improved, therapeutic results with less toxicity and more 
molecularly targeted pathways should be the ultimate goal. Childhood cancer survivors are 
expected to live many years beyond their treatment and the side-effects o treatment can take 
many years to manifest themselves, preventing survivors from fully achieving their potential.
152
 
These long-term risks can include a second cancer diagnosis, chronic health conditions such as 
myocardial infarctions, neurocognitive defects, and psychosocial effects of their disease and 
treatment.
153
 
Psychosocial and behavioral studies in cooperative group research have overlooked many 
topics and represent a potential area for growth and development. Within cooperative clinical 
group trials, the primary focus of psychosocial behavioral research has been on the 
neurocognitive consequences of treatment. Here, there is an opportunity to further evaluate 
phenomena such as family dynamics during the cancer experience, remedial interventions of 
learning disabilities, assessments of child and family function, and methods to decrease aversion 
to treatment because of pain and discomfort. Individual researchers have taken the lead on 
evaluating quality of life, coping, and psychosocial functioning in these patients but the 
cooperative infrastructure of pediatric oncology offers further avenues of research. 
 Multi-institution studies would allow access to large numbers of children with similar 
diseases and treatment, because of the uniformity in protocols across consortium participants, 
and therefore create more significant results. Studies performed within the same institutions 
usually include children with different cancers undergoing a variety of treatments, including 
modes of therapy, which reduces the statistical power of such studies. Large clinical trials offer 
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opportunities to understand correlative links between biological, genetic, and clinical data and 
psychosocial phenomenon. This can help understand associations which improve treatment 
efficacy, reduce toxicity, and improve quality of life. Incorporating these types of studies within 
cooperative groups also offers access to enrolling and tracking participants over a large number 
of years. There is an emerging emphasis on the later consequences of disease and treatment and 
cooperative trial participant databases would enhance such data collection and understanding.
154
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5 Expansion to Other Diseases and Fields of Medicine 
 The accomplishments of pediatric oncology hold valuable potential for applications to 
adult oncology. There are many characteristics of the pediatric cancer model which could 
transform care in adult patients and greatly improve outcomes if it were to be applied in a 
judicious and strategic manner. Applying some of the collaborative traits of childhood cancer to 
adult cancer could serve as the catalyst for overcoming the current roadblocks to progress or 
stagnation in advancement.  
The collaborative model of pediatric oncology could be applied to any field of medicine 
to yield improved results. While pediatric oncology clearly has elements which could be easily 
translated to adult oncology to bring improvements, it can also serve as a model for other fields 
of medicine. The lessons and successes of this model can lead to innovations in therapy, 
improved delivery of healthcare, better patient experiences. First, areas of growth within adult 
oncology will be discussed. Next, categories of diseases which could benefit from a collaborative 
treatment and research model will be discussed. Finally, Alzheimer’s, a relatively common 
disease with high levels of funding but little biological understanding, will be explored as a non-
oncological case study for collaboration expansion. 
5.1  Expansion to Adult Oncology 
 The collaborative model established in pediatric oncology has the potential to transform 
the nature of care and success in the field of adult oncology. Five-year cancer survival rates for 
adults are higher now than at any time in the past and cancer incidence rates are also 
decreasing.
155
 Although mortality rates have declined in every state, the extent to which they 
have varies in magnitude between different regions of the United States. Between the early 
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1990’s and 2011, declines ranged from 9% in Oklahoma to 33% in the District of Columbia. 
Generally, Southern states had the slowest declines and highest current death rates while the 
Northeastern states had much higher declines.
156
 Expansion of multi-institutional clinical trials in 
adult oncology can potentially mitigate these differences by bringing treatments to the smaller 
centers which are more likely to be found in rural areas. Existing cancer knowledge cannot be 
applied to all segments of the population if there is no structure to disseminate treatment to 
individuals who are physically isolated from the large centers where most of the breakthrough 
discoveries are occurring. 
 Because the most anticancer drugs are developed for adults, there is not a shortage of 
sufficient pharmaceutical treatments for treating adult malignancies. However, as the biological 
understanding of cancer is progressing, it is becoming increasingly apparent that cancers need to 
be grouped based on their subtype.
157
 Until now, adult oncology has been able to pursue 
successful trials despite the fact that only 3% of patients participate in one at some point in their 
treatment.
158
 As cancers are classified into smaller and smaller groups, the same issue of number 
of trial participants that is found in pediatric oncology rises. “Common cancers” are increasingly 
becoming fragmented into smaller molecular subsets, and therefore substantially increasing the 
number of rare cancers.
159
  In order to reach sufficient numbers for phase II and phase III of the 
trials, hospitals, research institutes, and pharmaceutical companies will need to collaborate. 
 The creation of a consortium to oversee trials could also be extremely beneficial. While 
creating one consortium for all cancers would likely be unfeasible and ineffective, having an 
organization serve as an overseer for all breast cancers or all blood cancers would likely increase 
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the rate of treatment development. A consortium of this type would be able to bridge barriers 
between the numerous academic and clinical institutions. 
 Furthermore, a replication crisis has been identified in biomedicine due to weak 
experimental designs, contamination, and sloppy data analysis.
160
 A study performed in 2015 
found that over 50% of preclinical research was irreproducible, resulting in a waste of over $28 
billion.
161
 Following the model created by PPTP and having one organization perform preclinical 
identification of treatments by providing access to a variety of tumor samples could be very 
effective. A consortium would act essentially as a supervisor by creating uniform standards, 
aligning stakeholder priorities, and standardizing procedures and, as a result, address much of the 
inefficiency and weaknesses of the system. As cancers are increasingly fragmented, the number 
of trials could also increase inefficiently with overlap occurring. Especially when the cost of 
research is already increasing substantially, there needs to be enhanced communication, both 
nationally and internationally, to promote group efforts rather than waste resources on multiple 
trials addressing the same topic.
162
  
 The well-established integration of the interdisciplinary team and the fact that it is an 
expected part of treating cancer is not a phenomenon present in adult oncology. The concept of 
team-based care already exists within oncology, known as the multidisciplinary care team 
(MDT) which was based on the tumor board, but is composed of physicans of different 
specialties. Additionally, oncology care within these teams is not coordinated and the burden of 
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doing so often falls on the patient.
163
 A change which would perhaps have the most direct impact 
on the lives of patients is a greater incorporation of multidisciplinary treatment into adult 
oncology. Integrating counseling services into cancer treatment and establishing it as common 
practice would be especially important in providing patients with the mental support during an 
extremely vulnerable time. Many patients still do not receive adequate psychosocial care
164
 
despite numerous studies outlining the need for such services.  
 While providers may interact dynamically, they do not always work interdependently or 
adapt to achieve common goals. The team may share the same goal of improving the health of 
the patient but personal and professional goals, hierarchal rigidity, and incomplete information as 
the patient moves between providers may impede collaboration. In reality, adult oncological care 
is provided by a team of teams which only increases the potential for inefficient, uncoordinated, 
and sometimes suboptimal care.
165
    
 When expanding the role of teams and collaborative care within adult oncology the 
importance of organizational environment should not be forgotten. The organization in which the 
team resides must also be able to support teamwork, this includes supporting, reinforcing, 
measuring, and developing team-based behaviors and attitudes. The cancer care team cannot 
excel without optimal organizational conditions.
166
 Although it may have room for improvement 
on this front, pediatric oncology institutions have fostered teamwork. Translating the 
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collaborative model to adult oncology will require that the organizations and institutions of that 
field provide the same environmental support.  
 Because expanding the use of collaborative teams would be a dynamic change, patient 
advocates should be to not only ensure a focus on patient voices but also to help facilitate 
teamwork. Patient advocates bring in the viewpoints, needs, and concerns of patients into the 
teams comprised of clinicians, researchers, and other healthcare professionals. The patient 
advocate ensures a patient-centric approach as the managerial aspects of providing healthcare 
undergo changes. One large barrier to effective teamwork within and between organizations is 
incompatible Electronic Health Records (EHRs). Even when the EHR system is less than ideal, 
patient advocates can serve as a point of communication between the different institutions.
167
   
 Within adult populations, increasing the disciplinary diversity of oncology teams can not 
only allow comprehensive care of the whole patient but also address barriers to care. Different 
disciplines have different approaches to asking an adult patient about their cancer and 
interpreting that information. Consequently, when these perspectives are combined, medical and 
nonmedical barriers to care may be identified. Such barriers may have cultural, financial, or 
psychosocial, socioeconomic, or health literacy bases.
168
 Especially when patients of different 
cultural and socioeconomic backgrounds come to receive treatment, disciplinary diversity can 
improve the healthcare they receive.  
One cause of this may be a larger societal issue of not addressing mental health issues 
and stigmatizing those who may be mentally troubled. Perhaps the system does not provide a 
mandate for this type of mental health support in an effort to respect the wishes of adults, who 
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presumably would be able to articulate a desire for such services, and not force unwanted 
treatment. These services are not provided as an option to children; they are integrated into the 
treatment plan, partially because pediatric oncology treatment focuses much more on quality of 
life after survival than adult oncology. Currently, the professional standards of the Commission 
on Cancer mandate that all cancer patients must be screened at least once for psychosocial 
distress. While heightened awareness of this issue is a step in the right direction, psychosocial 
support services should be a well-integrated aspect of care from the onset of treatment and not 
only a crisis management mechanism.  As survival rates for adults are increasing and the field is 
increasingly addressing survivorship-related issues, providing more and better psychosocial 
services will be key in improving health outcomes.  
Pediatric oncology can also inform on other aspects of treating adult oncology. The focus 
of care in pediatric oncology always includes the family and treatment centers are staffed and 
physically set up to address the needs of parents and siblings in addition to the patient’s. In the 
adult setting, families and friends have begun to play a larger role in an individual’s treatment 
yet they are not given the same resources and support for doing so. Especially when cancer care 
is provided in an outpatient realm the needs of families and friends are increasingly under 
supported.
169
 It is clearly known that social support plays an integral role in coping with illness 
and improving health outcomes 
170
 and the health delivery system ought to assist in the needs of 
an individual’s social network.  
When treating children, pediatric oncologists are very cognizant of the developmental 
effects chemotherapy or the therapies may have. There is a significant amount of focus placed on 
potential adverse effects to other organs as well as potential intellectual and emotional 
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development. These functional outcomes receive much less attention in the adult setting. Simply 
starting treatment takes precedence over considerations regarding fertility, family, work and 
social roles, and economic situations. As a result, it often becomes too late to take advantage of 
late-effect considerations, such as sperm or ovarian tissue banking.
171
 While traditional 
oncologists may not address these issues early enough, integrating a multidisciplinary team could 
bring earlier focus to late-term developmental consequences to the benefit of the patient.  
As described earlier, pediatric oncology treatments take note of the patient’s age as well 
as current and future functional status simply because they are expected to live longer and 
remain members of society. Consequently, when new information regarding the adverse effects 
of treatment becomes available, changes in standard therapy are made very quickly, partially 
because of the centralized and well-organized consortium approach. In the adult setting, 
however, oncologists often make recommendations without considering the patient’s potential 
life span, preferences, or potential for an active lifestyle. The aging population is becoming 
healthier and patients are increasingly requesting therapies which maintain the ability to pursue 
life goals and meaningful activities. Adult oncologists, therefore, ought to utilize research on 
quality-of-life outcomes more.
172
  
As morose as it may seem, the traditional viewpoint has been that oncology patients of a 
higher age simply do not have as much time left to pursue goals, maintain an active lifestyle, or 
contribute to society. With changes in technology and overall health status, this perspective 
needs to evolve in conjunction with the demographic shifts that are occurring. Leading 
meaningful lives after treatment is increasingly becoming a possibility for middle-aged and older 
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patients, and there ought to be greater efforts to maintain a high quality of life both during and 
after treatment.  
From a societal standpoint there seems to be a greater ease in dedicating greater resources 
to the pediatric patient, both because they have their whole life ahead of them and investing in 
their survival is a smart choice and also because these children have no personal responsibility in 
their diagnosis. For many adult patients, cancer may have been caused by poor lifestyle choices 
and spending large amount of money on them sometimes seems less justifiable, especially when 
they have fewer years left to live. However, society has already invested in these adults in a 
variety of ways for a long amount of time and so providing better cancer care may be a way to 
ensure the earlier investments are not lost. Additionally, many of the reasons for poor lifestyle 
choices may be caused by societal inequalities rather than individual choice and every member 
of society ought to receive the best medical care possible regardless of their previous conditions. 
Finally, pediatric oncologists understand the long-term challenges a family and patient 
can face years after treatment has been completed. These patients require long-term follow up 
care and the pediatric community is exploring which types of physicians should be overseeing 
this process. Even though this exists in the adult realm, the subsequent physicians are often 
primary care doctors who are less familiar than oncologists on the late effects of cancer 
treatments. Non-oncology specialists may not understand how treatments were given years ago 
and may not know the long-term psychosocial, genetics, and applied therapy risks. As children 
transition into adulthood and begin seeing a different type of provider, such lack of informational 
knowledge becomes more pressing.
173
 Adult who are childhood survivors of cancer often do not 
remember the details of their treatment, such as the different therapies they received and their 
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long-term risks, and this lack of knowledge can lead to suboptimal long-term care.
174
 The 
Children’s Oncology Group is currently working to establish a treatment summary form which 
would be provided to patients and their families at the end of treatment. Expanding this model 
into adult practice could improve the follow-up care of survivors of all ages so that their health 
care providers can discuss, design, and deliver the best possible care.  
5.2 Lessons for Other Diseases 
It is clear that greater collaboration in a variety of field of medicines would lead to 
improved outcomes and greater innovation in therapies. However, certain diseases and areas may 
be more conducive to the pediatric oncology model because of the conditional similarities they 
share with the disease. These similar diseases have an untapped potential for large growth and 
development in scientific understanding, treatment, and long-term survivorship.  
There are certain characteristics which may make a disease more apt for introduction of 
greater teamwork and coordination. One, having large amounts of research funding and a public 
willing to donate significantly to the disease would incentivize the creation of a consortia 
approach. While childhood cancers may not receive as much pharmaceutical attention, much of 
the early growth in the field happened because individuals and society were willing to donate 
large sums of money to uncover the scientific principles of the disease. Other childhood diseases 
and Alzheimer’s, for example, have a high allocation of resources and could benefit from 
collaboration. 
 This leads to a second characteristic of having limited scientific understanding of the 
principles underlying the disease, either caused by low incidence numbers or just general lack of 
knowledge. The first breakthrough success in pediatric oncology was in ALL and occurred 
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because researchers were desperate to make some sort of progress and stumbled upon 
multimodal therapies as highly effective therapeutic agents. Coordinated trials and research 
collaboration among the public and private sectors could facilitate a more rapid pace of 
development in diseases such as Alzheimer’s. Rare diseases with low incidence numbers in both 
children and adults, such as Neglected Tropical Diseases (NTDs), have been shown to benefit 
from coordination of research to enhance trial participation.  
Alternatively, if a disease lacks sufficient financial allocations then having an 
infrastructure which improves communication between different research entities would lead to a 
more efficient use of resources. Diseases such as alcoholism or conditions like migraines do not 
receive sufficient funding and therefore are under-researched because of social stigmas or 
misconceptions. Creating a system which allows for the sharing of data and results would 
capitalize the work that is being done. While this may be difficult given the competitive nature of 
research and the publish-or-perish phenomena, incentives for collaboration can be implemented 
at a low cost. 
Chronic diseases with no cure have already been shown to benefit from an 
interdisciplinary and collaborative treatment model. Patients with depression, diabetes, and 
coronary heart disease have faced significantly improved outcomes when treated with a 
collaborative care model and a medically supervised nurse.
175
 Other chronic diseases such as 
Crohn’s and Inflammatory Bowel Disorder which not only require management of multiple 
symptoms but as of yet have few promising therapies have the potential to undergo large 
transformations in growth.  
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Finally, patients who have been diagnosed with diseases with intense treatment, long-
term survival, and psychosocial consequences could be greater supported through the integration 
of multidisciplinary care. Providing psychological care to child cancer patients and having social 
workers and patient navigators work with families decreases the burden of the disease and 
supports the patient in living a meaningful life with as few long-term effects as possible years 
after completion of treatment. Making these types of services standard of practice in other 
diseases with deep psychological impact and long-term expected survival would improve the 
patient experience and lead to an overall improvement in health outcomes.  
5.3 Alzheimer’s: A Case Study 
 Alzheimer’s is a degenerative brain disease and is the most prevalent cause of dementia. 
It includes pathologic changes in the brain prior to the beginning of symptoms as well as the 
disease itself. Symptoms of Alzheimer’s include difficulty remembering, names, conversations, 
or events, apathy and depression, impaired communication, confusion, poor judgement, behavior 
changes, and difficulty performing everyday tasks such as speaking or walking. The 
accumulation of beta-amyloid plaques outside the neuron and tau protein buildup inside causes 
destruction of neurons.
176
 40 million individuals worldwide have Alzheimer’s and this number is 
expected to double every 20 years.
177
 In 2017, 5.5 million Americans are living with the 
disease.
178
 
 Most Alzheimer’s patients receive treatment for their care from general physicians and 
increasing collaborative care within these environments can significantly improve Alzheimer’s 
treatments outcomes. Utilizing an interdisciplinary team led by an advanced practice nurse has 
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been shown to significantly improve quality of care and the behavioral and psychological 
symptoms of patients. These patients had fewer symptoms of dementia and improvements in 
depression, without a significant increase in the use of antipsychotics or sedative hypnotics.
179
 
Given the severity of symptoms of this disease and the high burden placed on caregivers, such 
significant improvements should be translated into practice. 
 Alzheimer’s has staggering socioeconomic costs with an estimation of $604 billion 
worldwide.
180
 Current therapies only address symptoms and only provide limited benefits to 
patients
181
, contributing to a significant need for the development of novel and more effective 
therapies.  Recent late-stage drug failures in phase III trials have indicate a need for innovation 
within the research model for Alzheimer’s.  Increasing collaboration between academia, 
industry, and government at the mechanistic understanding level, allowing for precompetitive 
information sharing, and creating a multi-institutional funding model can lead to greater growth.   
 At later levels of drug development, a collaborative research network could provide the 
opportunity to standardize disease models, establish biobanks, and create a framework for data 
sharing. There are large gaps in understanding the underlying mechanisms of the disease which 
could be addressed through cooperative research. Identifying biomarkers for Alzheimer’s can 
have transformative effects on treatment, as was seen in pediatric oncology. Novel, 
precompetitive trials, which would reduce risk because it would be funded by all shareholders, 
have been identified as a method to test drugs and diagnostics collaboratively.
182
 Rather than 
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creating new initiatives, combining efforts would be a more efficient manner to take advantage 
of limited funding and resources while providing the greatest benefit for patients.  
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6  Ethical Considerations 
 The treatment of cancer care is closely intertwined with the considerations of bioethics; 
treating children, especially those with serious life-threatening diseases, is wrought with moral 
and ethical dilemmas. Even though the ultimate goal may be providing medical care in order 
treat the disease, understanding the ethical foundations of scientific research and medical 
practice is necessary for good clinical care. Healthcare professionals in this field may find 
themselves in positions questioning what the “right” path is when families are under high levels 
of distress, children diagnosed with cancer are extremely vulnerable, and there is a strong 
commitment to finding a cure. Important ethical issues within this field can include: disclosure, 
assent, informed consent, and medical late effects.
183
  Ethical principles ought to be an important 
consideration in the treatment of children with cancer in order to provide the most beneficial and 
morally appropriate care possible. 
6.1 Ethical Complications in Decision Making 
The moral imperative to pursue pediatric oncology research is strong; after all, cancer 
kills more children than any other disease. Ethical pediatric treatment is dictated on the 
principles of beneficence and non-maleficence; that the treatment should be in the best interest of 
the child. Research, however, also contains the added component of benefit to others and 
therefore autonomy is the prevailing principle. This principle of autonomy mandates that 
subjects participate in research voluntarily, with adequate information, and after giving explicit 
consent.
184
   As clinical trials are not only designed to test the efficacy of cancer therapies but 
also its toxic effects, there are numerous ethical considerations surrounding the participation of 
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children in research trials.
185
 Informed consent is the first step of the process in trial participation 
and is necessary for a child to be enrolled in a trial. 
The close relationship between research and care in pediatric oncology creates challenges 
for the principle of voluntariness of informed consent of parents for their child’s participation in 
clinical trials.
186
 Parents are the principal decision makers for their child’s involvement in cancer 
research as young children have not developed enough to make choices that are fully voluntary, 
autonomous, and competent.
187
 Informed consent for research is often required immediately after 
diagnosis, and when parents are in shock and disbelief their decision to enroll in research may 
not be fully intentional, thus not making the consent fully voluntary.
188
  
Because minors lack the competence to make informed decisions, their parents serve as 
surrogate decision makers. The pediatric patient is so dependent on the adult caregiver that they 
must express their autonomy through others.
189
 In fact, the American Association of Pediatrics’ 
Bioethics Committee has declared that the “doctrine of informed consent has only limited direct 
applications in pediatric oncology.”190 This, of course, raises the question of how surrogates 
should decide. The best interest standard has been regarded as the best solution to the challenge 
of substituted judgement. In the best interest standard the surrogates are held to make decisions 
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based on what is best for the child, not what they think is the best choice for themselves, what 
they would prefer, or what they think the child would want.
191
   
Quality informed consent is a bedrock of ethics in research practices. Pediatric cancer 
phase I trials face unique and multiple ethical challenges, yet many parents whose children 
participate in phase I trials do not understand the specific purpose of these trials. Upon 
interviewing parents after informed consent conferences (ICC) between the physician and 
parents, it was found that only 32% of parents had a substantial understanding of the purpose of 
phase I trials and 35% demonstrated little or no understanding. Doctors oftentimes also failed to 
disclose important aspects of medical regimens during these phases, such as drug safety 
(explained in 23% of ICCs), dose finding (52% of ICCs, and dose escalation (53% of ICCs). 
This clearly demonstrates an issue in physician-parent communication that needs to be overcome 
in order to improve quality of care.
192
 
6.2 Ethical Implications of Phase I Trials 
  Phase I trials are perhaps what pose the most ethical dilemmas as they test an agent on 
human subjects for the first time. The ethical discussion in this area usually centers on the 
question of direct benefit. Even though meta-analyses have found that there is only a small 
clinical response rate in Phase I cancer trials, it is also argued that any chance of direct benefit 
qualifies as “prospect”. Here is where the dichotomy between research and clinical medicine 
becomes significant; the scientific intent of Phase I is to find dosage guidelines but the clinical 
intent is to provide beneficial medical treatment to the patient.  
 The first phase of trials contains its own concerns for Phase I studies. Phase I trials 
expose children to more than minimal risk, and raise the question of whether parents can provide 
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informed consent for such trials given the poor chance of response. Generally, the only 
alternatives to Phase I trials are palliative care only or continuing failed therapies. However, 
because there is a very small chance of chance of response the Phase I trial can be considered 
comparable to the potential benefits from the two alternative options given that the trials are 
rational and well-designed. 
193
  
 Therapeutic intent must be considered when undertaking participation in a phase I trial 
because otherwise a child may be unnecessarily exposed to side effects, discomfort, and adverse 
events which is morally unjustifiable. Because these trials are not curative, determining 
therapeutic intent becomes more difficult and a thorough risk versus benefit assessment must be 
made. This risk vs. benefit analysis is critical in maintaining the principal of beneficence, which 
is defined as an obligation to do no harm while maximizing benefits and minimizing risks. These 
trials may, however, provide benefits through symptom relief, disease stabilization, and even 
maintenance of hope. The preliminary studies may be the last remaining treatment option and 
families may view the potential for any type of benefit, however rare it may be, as advantageous. 
While those who participate in these trials may not receive direct benefit, it will inform future 
patients. Given the ethical dilemma surrounding phase I trials, it is essential that families and 
patients are communicated with directly and clearly. They must be given and understand all 
possible options in order to make a fair and just decision.
194
  
6.3 Palliative and End of Life Care  
 The current state of oncological care has seen a massive shift towards increasingly 
aggressive treatment that does everything which is possible. Based on reports from surrogates 
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and patients the number of patients receiving “all care possible” increased from 7% in 2000 to 
58% in 2012, representing an increase by a factor of eight.
195
 While this data stemmed from adult 
patients, cancer treatment overall is becoming more aggressive.
196
 The National Cancer Board 
has already indicated that overly aggressive treatment may represent “poor quality care” as 
underuse has traditionally been focused on as a source of poor quality care and not overuse.
197
   
 Even though pediatric cancer patients face vastly different outcome potentials and 
demonstrate greater resilience to treatments, the value of palliative and end-of-life care should 
not be ignored. Palliative care is given to improve quality of life and help manage symptoms 
associated with the disease, including pain. The goal of palliative care is not to cure but rather to 
prevent or treat the symptoms and side effects associated with the disease and its treatment.
198
 It 
also addresses the physical, emotional, psychological, and spiritual needs of the patient 
compassionately.  Today, there is a greater understanding of the value of providing palliative 
care and professional institutions such as the Commission on Cancer and College of Surgeons 
have mandated that palliative services be a component of the patient’s treatment.199 However, 
this resource should be used from the beginning of treatment and not only in instances of crisis. 
 Hospice in, in contrast, is directed towards those in the terminal stages of their cancer or 
with a terminal prognosis. While it encompasses many of the same principles of palliative care, 
Hospice focuses more on improving quality-of-life, promoting decision making in the end-of-life 
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process and supporting grieving. Due to the Medicaid structure of the United States, Hospice is 
generally limited to the last six months of a patient’s life.200 
 Providing palliative or hospice care should not be viewed as giving up hope. Dying 
children may seem contrary to the natural order but referral to an end-of-life program should not 
be translated into failure. Patients diagnosed with invasive cancers who receive palliative care 
not only have a higher quality of life but also live longer lives.
201
 Additionally, it has also been 
found that terminal patients who receive hospice care live longer than those who do not.
202
 While 
utilizing these services may be viewed as accepting defeat, the reality is that they not only 
increase length of life but significantly improve its quality. Patients who received aggressive end 
of life care actually had lower quality of life; therefore while reaching a cure should be a goal, 
the patient’s quality of life should also be prioritized. 
 Pediatric oncology faces unique circumstances within the realm of end-of-life care. 
Physicians and other healthcare providers already tend to shy away from difficult conversations 
surrounding prognosis and treatment due to lack of training, a desire to avoid uncomfortable 
conversations, and because childhood death is so rare. Furthermore, maintaining communication 
across different ages, developmental levels, and decision-making capacities is a complex skill set 
for physicians to master. Professionals who offer end-of-life care to adults, such as hospice staff, 
also may not have the training to be able to handle the complex psychological, physical, and 
emotional care of dying children and their families. 
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 The resilience of children and their ability to recover from situations which may be life-
threatening in adults causes providers and patient’s families to have different palliative care 
needs and recurrent end-of-life conversations at different points in time. Clinicians have a 
notoriously poor ability to predict death, a phenomenon even worse in those living with terminal 
illness for many years prior to their death. As such, the end-of-life needs of children and their 
families do not fit well into the medical, psychological, spiritual, and economic system created 
for adults. While the emotional capacity of each child may be different, they too need to 
participate to a certain extent relevant discussions and decisions in order to be able to manage 
and cope with their own grief, say good-byes, and gain some sense of control over their death.
203
 
While a pediatric cancer patient may not be able to make autonomous decisions in trial 
participation, they should maintain a stake in their own dying process. 
 The American Academy of Pediatrics called for integrated care in 2000 in order to 
provide access to palliative services early in the course of treatment. Despite this, palliative care 
has been fragmented because of a lack of empirical data of palliative care effectiveness, 
reimbursement issues, and a lack of palliative care experts.
204
 Only 10% of pediatric oncologists 
formally studied pediatric terminal care, and almost 50% have reported lack of access to a 
palliative care team.
205
 As a result, children and families participating in trials or treatment may 
not be able to receive access to those services or to information they would need to transition 
into end-of-life care. 
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Increasing the enrollment of children in Phase I oncology trials would greatly increase 
the ability of researchers to develop new treatments and improve overall medical care. Especially 
given the need to develop new anticancer agents which target specific histologic malignancies, 
due to the high variability in pediatric tumors, more clinical trials will be necessary. One 
potential way to mitigate the low benefits of Phase I trials could be by integrating it with 
palliative care. Parents should not have to be forced to choose between trial participation and 
palliative or end-of-life care. While the research protocol would dictate the management of 
toxicities in Phase I trials, integrating palliative services into the protocol may augment pain 
management and other support measures to improve the patient’s quality of life.206  
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7 Significance, Limitations, Future Directions 
  This paper has chosen to focus on the pediatric oncology model specific to the United 
States, a prototype which is very similar to that in European countries. There are, however, 
significant disparities in international treatment methods of pediatric oncology, especially in 
developing countries which need to be addressed if there is to be equitable treatment for this 
disease. The dramatic growth in survival rate is a Western phenomenon, and many countries still 
have low survival rates. 80% of the world’s children live in low and middle-income countries 
(LMICs) and the 200,000 children diagnosed their annually have very limited access to treatment 
and therapies, and of those only 25% survive. While other diseases such as malaria, diarrhea, and 
malaria account for a much larger proportion of ailments in these countries, affecting 5 million 
children annually, there is a still an importance for the treating children with cancer especially 
when curative therapies occur.
207
 Bringing a more stable treatment structure to LMICs would 
also expand the potential number of children that could be enrolled into clinical trials and thus 
lead to more significant results and faster research advancements.  
 Regional collaborative initiatives that work directly with healthcare providers and the 
population can reach out to almost 60% of children with cancer worldwide. A major challenge 
over the next few decades will be how to translate the developments made in countries with high 
levels of resources to children in all geographical locations. There is very little known about the 
epidemiology of childhood cancers in LMICs and working with local governments to bolster 
their national registries could lead to important improvements.
208
 Improving cancer outcomes in 
LMICs will require innovative solutions as strategies used in high-income countries cannot be 
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directly applied there. It will be necessary to move beyond current standards and towards novel 
methods for finding and applying evidence-based therapies to low-resource settings.
209
 While 
there is clearly area for further growth within the United States, global populations should not be 
forgotten and efforts should be directed to bring treatment to children in all areas.  
 While the collaborative model would bring significant improvements to healthcare, there 
are barriers towards such a system and the practical aspects of implementation may be difficult. 
One, a model of this sort would require a significant commitment of resources both financially 
and professionally. Creating consortia models would require physicians and researchers to move 
away from competitive cultural norms and the publish-or-perish phenomena. Policy changes 
would have to be made to incentivize collaboration and lower regulatory impediments.  Some 
may argue that this may drain resources away from more pressing healthcare needs and that 
support should instead be funneled to research and development rather than a systemic model.  
Electronic health records (EHRs) also pose a challenge to improving coordinated care 
between physicians and during research trials as there already numerous issues with sharing 
information caused by incompatible systems. A collaborative system needs a technological 
infrastructure that allows for sharing information but the current flaws in EHRs make this aspect 
a challenge. Problems which physicians have cited with EHRs include insufficient standards, 
concerns about privacy rules, difficulties matching laptops, and costs.
210
 While a consortium 
system like the Children’s Oncology Group offers a streamlined method to consolidate patient 
data among institutions, medical fields which lack such an entity would face more difficulties in 
sharing data. Sharing data also raises concerns about patient privacy. Personal patient 
information, including history and details of treatment, would be viewed by many more players 
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in a collaborative system including a greater number of researchers or institutions and healthcare 
providers that are not doctors such as nutritionists or physical therapists. Growth in collaborative 
models should be cognizant of issues in patient privacy and should expand in ways that ethically 
preserve the rights of patients.  
Additionally, there are merits to a competitive system as it has fueled growth and 
innovation in numerous sectors of this country’s economy. Simply put, it is an integral 
component of the American capitalist system. Many believe that competition is the ideal and 
most efficient method for innovation and discouraging it would have more negative impact than 
benefit. When one of the primary goals is to spur innovation, the question then becomes how to 
best balance competition and collaboration. When there are so many stakeholders involved, 
including pharmaceutical companies, academia, hospitals, disease advocacy groups, etc., and 
each is regulated by different entities, creating uniform change becomes bureaucratically 
difficult. When compounded with different strategies and goals in every group, moving towards 
a collaborative system has major hurdles. Regulatory issues, standardization of practice, and 
intellectual property concerns would all have to be carefully managed.  
 Despite these challenges, collaboration in care and research holds significant value. 
Medicine ought to be patient-centric and the collaborative model leads to better results because it 
creates a better patient experience and focuses on the patient holistically. While advances in 
treatments and acceleration of research are important goals, the ultimate goal of medicine is to 
heal the patient. Collaborations in research place the patient before financial reward and 
collaboration in treatment allows the patient to supersede physician competition and receive 
holistic care that addresses all aspects of their sickness. Managing only the disease itself is not 
and should not be the only goal – the patient’s psychological well-being, family support, and 
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long-term health also need to be treated and the collaborative model is one of the most efficient 
and effective ways to do so. Quality of life is greatly improved through a collaborative treatment 
approach. 
 Given the current climate surrounding the state of research it is becoming increasingly 
important to perform it with greater efficiency. Biomedical, scientific, and medical research are 
facing seismic cuts under the current presidential administration. As of early April 2017, 
President Trump has proposed to cut biomedical research by 18% by reducing the National 
Institute of Health budget by $5.8 billion.
211
 While it is still uncertain whether Congress will 
support such cuts in biomedical research,
212
 these proposals are representative of a larger issue of 
misconceptions of research and desire to move resources away from research.  
Cooperative research models can mitigate the negative consequences of reduced funding 
and lead to a more efficient use of limited resources. Overlap is reduced and mechanisms to 
share data, such as through patient registries and biobanks, are created to the benefit of all 
players. Conflict of interest issues would be diminished as players align goals and mission from 
the beginning of the process, thus allowing faster translation of research developments into the 
clinical setting. As more drugs are created using genomic information and molecular targeting, 
precompetitive collaboration leads to a faster marketing of new agents because the preliminary 
scientific knowledge that these advancements rest on is shared amongst developers. The need for 
innovation within research remains critical – while the costs of developing pharmaceutical agents 
are rising, the pharma success rate is decreasing.
213
 The pharmaceutical industry as a whole 
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could benefit from modifications in structure to expand its cooperative efforts in order to yield 
better return on its investments. 
This project has many avenues for growth and development. Interviewing pediatric 
oncologists may provide further insight into how collaborative practices are ingrained into the 
everyday lives of a practicing physician. Further understanding the specific dynamics and 
characteristics would provide more informed recommendations on translating this model to other 
medical fields. Scientific research is beginning to enter new fields, driven by advancements and 
technology and a greater understanding of the genome, especially with a growth towards 
personalized medicine. It is still unknown how these advancements will shape the nature of 
research in the future but identifying key niches for implementing collaboration could accelerate 
growth further. Further research can be performed on what types of policy changes may be need 
to be made to accommodate for application of this model. Specific areas of interest include 
health insurance policies, governmental guidelines for drug development, and intellectual 
property laws. 
 Finally, this project has explored what conditions may make a disease or medical field 
more conducive to the application of the collaborative pediatric oncological model. Identifying a 
few specific diseases with the most potential for benefit would allow for a more concrete 
expansion in cooperative care. . Performing economic and financial analyses on the potential 
costs to apply this model to fields outside of pediatric oncology would provide a better 
understanding on what aspects of the model should be applied and to what fields. Cost-benefit 
analyses would help inform a more efficient application of the model and would reduce wasted 
resources and time. 
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8   Conclusion 
 The purpose of this paper was to approach the field of pediatric oncology not from a 
medical or scientific perspective but from the viewpoint of innovation. Especially after 
overcoming a huge lack of scientific mechanisms that underlay childhood cancers to ultimately 
lead to extremely high treatment outcomes, it becomes apparent that this field of medicine has 
very unique characteristics that have led to its high success rate. By pinpointing these specific 
traits and understand what attributes and conditions allowed for the rise of such a successful 
model, the core transformative characteristics of pediatric oncology can be applied to other 
fields. Encouraging innovation is no easy task, especially when there are a multitude of 
stakeholders involved in the process yet pediatric oncology has managed to transform this 
impediment into a driving force for positive outcomes. The growth demonstrated in this field can 
be attributed to its collaborative practices, both in treatment and research, and it is this high level 
of cooperation that can ultimately transform other areas of medicine.  
The success of pediatric oncology is an achievement that should be lauded, not only for 
the incredible growth and development it has seen over the last few decades but for its ability to 
unify players from all disciplines and even countries to address a single, important cause. The 
incorporation of collaboration has been fueled by necessity; the importance of these patients has 
motivated governmental agencies, institutions, and society to allocate a very large amount of 
resources to a small subsection of the population. This model has incredible potential to address 
a variety of other health issues facing the world today; collaborative efforts of this sort could be 
very effective in not only treating adult oncology but also a wide range of other diseases.  
 As technologies continue to progress and the scientific understanding of cancer becomes 
increasingly complex, it is important to continue addressing the issues that pediatric oncology 
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still faces. While many cancers have high success rates, most neurological and central nervous 
system cancers have a very low probability of survival. In order to address these cases as well as 
the decline in growth over the last decade, the introduction of new methods and policies is vital 
in sustaining progress. The model of pediatric oncology in the United States has managed to 
become a paradigm for successful research and treatment, and its incorporation of collaboration 
is a standard that should be applied to other industries to foster innovation. 
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